Prognosis and complete remission rate of diffuse large B-cell lymphoma patients in standard R-CHOP with reduction of vincristine: A retrospective study.
| Autor: | Riasi F; Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran., Ataei Azimi S; Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran., Allahyari A; Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran., Moeini Nodeh M; Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran., Shakeri MT; Department of Biostatistics, School of Health Mashhad University of Medical Sciences Mashhad Iran., Kamandi M; Department of Internal Medicine, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Health science reports [Health Sci Rep] 2023 Nov 28; Vol. 6 (12), pp. e1716. Date of Electronic Publication: 2023 Nov 28 (Print Publication: 2023). |
| DOI: | 10.1002/hsr2.1716 |
| Abstrakt: | Background and Aims: The effect of stopping or reducing the dose of vincristine in diffuse large B-cell lymphoma (DLBCL) on the outcome and prognosis of the disease is still in doubt. The present study aimed to investigate and compare the prognosis and complete remission of two R-CHOP treatment regimens with and without vincristine reduction in DLBCL patients. Methods: This retrospective study was conducted on newly diagnosed DLBCL patients during 2018-2021. The patients were over 18 years of age, had been histologically confirmed by a pathologist, and were under treatment with R-CHOP regimen. The clinical information of the subjects as well as the number of treatment courses were extracted from their medical records and then compared. Results: Overall, 269 patients with DLBCL were included in this study, 15.99% of whom ( n = 43) had vincristine reduction. There was no significant difference between the studied factors regarding the reduction of vincristine and the complete R-CHOP regimen ( p > 0.05). Besides, no difference was observed in the 1-year overall survival (OS) and progression-free survival (PFS) of the patients in the two groups treated with R-CHOP regimen with and without vincristine reduction ( p > 0.05). The complete remission rates of the patients treated with R-CHOP regimen with and without vincristine ( p > 0.05) were not different either. The results of the Cox multivariate regression showed that reducing the dose of vincristine from the R-CHOP treatment regimen had no relationship with the 1-year OS and PFS of the DLBCL patients (hazard ratio [HR] Conclusion: The results of this study showed that the reduction of vincristine from the R-CHOP regimen in the DLBCL patients was not likely to make a difference in the 1-year OS and PFS of the patients. However, further studies are needed on the issue. Competing Interests: The authors declare no conflict of interest. (© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text